Effect of a Somatostatin Analogue (SMS 201–995) on Antral Gastrin Cell Hyperplasia and Hypergastrinemia Induced by a Histamine H₂-Receptor Antagonist

References

• Carney J A, Go V LM, Fairbancs V F. The syndrome of gastric argyrophyll carcinoid tumors and non-antral gastric atrophy. Ann Intern Med 1983; 99: 761–6
   PubMed Web of Science ®Google Scholar
• Solcia E, Capella C, Vassallo G. Endocrine cells of the stomach and pancreas in states of gastric hypersecretion. Rendic R Gastroenterol 1970; 2: 147–58
   Google Scholar
• Mignon M, Lehy T, Bonnefond A. Development of gastric argyrophyl carcinoid tumors in a case of Zollinger-Ellison syndrome with primary hyperparathyroidism during long-term antisecretory treatment. Cancer 1987; 59: 1959–62
   PubMed Web of Science ®Google Scholar
• Kimura K, Kashiwagi H, Umezawa M. Control gastric acid secretion of gastrinoma [in Japanese]. Ibunpitu Kenkyukaishi 1991; 23: 41–4
   Google Scholar
• Ekman L, Hansson E, Havu E. Texicological studies on omeprazole. Scand J Gastroenterol 1985; 20(Suppl 108)53–69
   Google Scholar
• Axelson J, Håkanson R, Rosengren E. Hypergastrinemia induced by acid blockade evokes ECL cell hyperplasia in chicken, hamster, and guinea pig stomach. Cell Tissue Res 1988; 254: 511–6
   PubMed Web of Science ®Google Scholar
• Bordi C, Cocconi G, Togni R. Gastric endocrine cell proliferation, association with Zollinger-Ellison syndrome. Arch Pathol 1974; 98: 274–8
   PubMedGoogle Scholar
• Harvey R F, Davidson C M, Bradshaw M J. Multifocal gastric carcinoid tumors, achlorhyrdia, and hypergastrinemia. Lancet 1985; 2: 951–4
   Google Scholar
• Larsson H, Carlsson E, Mattsson H. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Gastroenterology 1986; 90: 391–9
   PubMed Web of Science ®Google Scholar
• Brazeau P, Vale W, Burgus R. Hypothalamic polypeptide that inhibits the secretion of immuno-reactive pituitary growth hormone. Science 1973; 179: 77–9
   PubMed Web of Science ®Google Scholar
• Barros D'Sa A AJ, Bloom S R, Baron J H. Direct inhibition of gastric acid and by growth-hormone release-inhibiting hormone in dogs. Lancet 1975; 1: 886–7
   PubMedGoogle Scholar
• Lehy T, Dubrasquet M, Bonfils S. Effect of somatostatin on normal and gastrin-stimulated cell proliferation in the gastric and intestinal mucosae of the rat. Digestion 1979; 19: 99–109
   PubMed Web of Science ®Google Scholar
• Bauel W, Briner U, Doepfner W. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–40
   PubMedGoogle Scholar
• Ellison E C. Suppression of gastrin and gastric acid secretion in the Zollinger-Ellison syndrome by long-acting somatostatin (SMS 201–995). Scand J Gastroenterol 1986; 21(Suppl 119)206–11
   Google Scholar
• Kimura K, Kashiwagi H, Fukuchi Y. Inhibiting effect of somatostatin analog (SMS 201–995) on gastrin secretion [in Japanese]. Prog Med 1991; 11: 2257–61
   Google Scholar
• Kimura K, Kashiwagi H, Fukuchi Y. Inhibiting effects of somatostatin analog (SMS 201–995) on gastric acid output and gastrin secretion [in Japanese]. Gut hormone. Igaku Tosho Shuppan, Japan 1992; Vol. XI.: 425–31
   Google Scholar
• Weber C, Merriam L, Koschitzky T. Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201–995: treatment of nude mouse xenografts. Surgery 1989; 106: 416–22
   PubMed Web of Science ®Google Scholar
• Poston G J, Townsend C M, Jr, Rajaraman S. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 1990; 5: 151–7
   PubMed Web of Science ®Google Scholar
• Maton P N. Effect of a long-acting somatostatin analog (SMS 201–995) in a patient with pancreatic cholera. N Engl J Med 1985; 312: 17–21
   PubMed Web of Science ®Google Scholar
• Kvols L K. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analog. N Engl J Med 1986; 315: 663–6
   PubMed Web of Science ®Google Scholar
• Clements D, Elias E. Regression of metastatic VIPoma with somatostatin analogue SMS 201–995. Lancet 1985; 2: 874–5
   Google Scholar
• Vinik A I, Tsai S T, Moattari A R. Somatostatin analog (SMS 201–995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med 1986; 81(Suppl 6B)23–40
   PubMedGoogle Scholar
• Takeda M, Takagi T, Maeno H. Kinetics of antisecretory action of a new H2-antagonist, YM-11170, in conscious dogs. Eur J Pharmacol 1983; 91: 371–6
   PubMed Web of Science ®Google Scholar
• Miyoshi A, Taniuchi A, Yanbana T. Inhibiting effect of H2-receptor antagonist (famotidine) on gastric acid secretion. Kiso To Rinsho 1983; 17: 2909–16
   Google Scholar
• Whitehouse I, Beglinger C, Fried M. The effect of an octapeptide somatostatin analog (SMS 201–995) and somatostatin-14 (SST-14) on pentagastrin-stimulated gastric acid secretion: a comparative study in man. Hepatogastroenterology 1984; 31: 227–9
   PubMedGoogle Scholar
• Gyr K E, Whitehouse I, Beglinger C. Human pharmacological effects of SMS 201–995 on gastric secretion. Scand J Gastroenterol 1986; 21(Suppl 119)96–102
   Google Scholar
• Christiansen J, Yotis A. The role of somatostatin and a long-acting analogue, SMS 201–995, in acute bleeding due to peptic ulceration. Scand J Gastroenterol 1986; 21(Suppl 119)109–14
   PubMedGoogle Scholar
• Umezawa M. Effects of long-term H2-receptor antagonist administration on antral G-cell serum gastrin concentration and gastric acid secretion [in Japanese]. Tokyo Jikeikai Med J 1987; 102: 531–42
   Google Scholar
• Fukuchi Y, Kashiwagi H, Umezawa M. Effect of long-term administration of H2-receptor antagonist on antral gastrin cell and epithelial cell proliferation in rats [in Japanese]. Ther Res 1990; 11(Suppl 1)171–6
   Google Scholar
• Fukuchi Y. Circadian rhythms in the number of gastrin cells, DNA synthesizing cells and labelling index of gastrin cell in the antral mucosa of the rat. Gastroenterol Jpn 1990; 25: 8–14
   PubMedGoogle Scholar
• Walsh J H. Role of gastrin as a trophic hormone. Digestion 1990; 47(Suppl 1)11–6
   PubMedGoogle Scholar
• Yassin R R, Clearfleld H R, Kats S M. Gastrin induction of mRNA expression in rat colonic epithelium in vitro. Peptide 1991; 12: 63–9
   PubMedGoogle Scholar
• Kayasseh L, Gyr K, Keller U. Somatostatin and cimetidine in peptic-ulcer haemorrhage. Lancet 1980; 1: 844–6
   PubMed Web of Science ®Google Scholar
• Antonioli A, Gandolfo M, Rigo G P. Somatostatin and cimetidine in the control of acute upper gastrointestinal bleeding. A controlled multicenter study. Hepatogastroenterology 1986; 33: 71–4
   PubMedGoogle Scholar
• Torres A J, Landa I, Hernandez F. Somatostatin in the treatment of severe upper gastrointestinal bleeding: a multi-center controlled trial. Br J Surg 1986; 73: 786–9
   PubMed Web of Science ®Google Scholar
• Galmiche J P, Cassigneul J, Faivre J. Somatostatin in peptic ulcer bleeding-results of a double-blind controlled trial. Int J Clin Pharmacol Res 1983; 5: 379–87
   Google Scholar
• Somerville K W, Henry D A, Davies J G. Somatostatin in treatment of haematemesis and melena. Lancet, 1: 130–2
   PubMedGoogle Scholar
• Christiansen J, Ottenjann R, Arx F V. Somatostatin analogue SMS 201–995 in peptic ulcer bleeding. Gastroenterology 1989; 97: 568–74
   PubMed Web of Science ®Google Scholar
• Pless J, Bauer W, Briner W. Chemistry and pharmacology of SMS 201–995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol 1986; 21(Suppl 119)54–64
   Web of Science ®Google Scholar
• Jackson I. Role of long-acting somatostatin analogue (SMS 201–995) in the treatment of acromegaly. Am J Med 1986; 81(Suppl 6B)94–101
   PubMedGoogle Scholar